September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Up-regulation of SLC2A9 (Glut9) in normal and diabetic human retina implicates altered urate transport in diabetes-induced retinal barrier dysfunction
Author Affiliations & Notes
  • Manuela Bartoli
    Ophthalmology, Medical College of Georgia -Augusta University, Augusta, Georgia, United States
  • Diana Gutsaeva
    Ophthalmology, Medical College of Georgia -Augusta University, Augusta, Georgia, United States
  • Menaka Thounaojam
    Ophthalmology, Medical College of Georgia -Augusta University, Augusta, Georgia, United States
  • Pamela M Martin
    Biochemistry and Molecular Biology, Medical College of georgia-Augusta University, Augusta, Georgia, United States
  • Folami Lamoke
    Biochemistry and Molecular Biology, Medical College of georgia-Augusta University, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Manuela Bartoli, None; Diana Gutsaeva, None; Menaka Thounaojam, None; Pamela Martin, None; Folami Lamoke, None
  • Footnotes
    Support  NIH/NEY EY22416
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3223. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Manuela Bartoli, Diana Gutsaeva, Menaka Thounaojam, Pamela M Martin, Folami Lamoke; Up-regulation of SLC2A9 (Glut9) in normal and diabetic human retina implicates altered urate transport in diabetes-induced retinal barrier dysfunction. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3223.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Our previous work has shown that in human DR there is increased production and deposition of urate at retinal tissue levels, thus, suggesting that urate metabolism and transport from and within retinal cells can play a contributing role in the pro-inflammatory events occurring in the diabetic retina. Here we have characterized the presence of the main urate transporter and putative glucose antiport SLC2A9 (Glut9) in retina and determined the effects of diabetes on its expression and immunolocalization.

Methods : Human post-mortem retinas from non-diabetic and diabetic donors were obtained from Georgia Eye Bank. Western blotting analysis and immunohistochemistry were performed using specific antibodies against human Glut9. Human retinal pigmented epithelial cells (ARPE19) and retinal endothelial cells (HuREC) in cultures were subjected to hyperglycemic stress (HG= 35mM D-glucose for 48hours) and clinically relevant doses of monosodium urate (MSU = 7mg/dL), alone or in combination with HG (MSU+HG). Cells treated in these conditions were then subjected to Western blotting analysis using specific antibodies against human Glut9

Results : Western analysis revealed the presence of Glut9 in human retinal tissues of non-diabetic and diabetic donors. In diabetic retinas this urate transporter was significantly up-regulated (>50%) in comparison to non-diabetic donors. Immunohistochemical analysis revealed that Glut9-specific immunoreactivity was primarily localized in the luminal side of retinal and choroidal blood vessels and the apical side of the retinal pigment epithelium (RPE). Glut9 immunoreactivity also was increased in the diabetic human retinas. Western analysis showed increased expression levels in ARPE19 and HuREC exposed to HG and MSU, however this was much more pronounced in cells treated with HG+MSU simultaneously.

Conclusions : Our data show, for the first time, that the urate transporter SLC2A9 (Glut9) is expressed in human retina and its expression is up-regulated in the diabetic milieu. Most importantly, Glut9 is primarily immunolocalized in retinal cells devoted to maintenance of the blood retinal barrier further underscoring the potential implication of retinal urate transport and metabolism in the development of DME and in DR progression.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×